| Literature DB >> 27739922 |
Luciana De Luca1, Giovanni D'Arena2, Vittorio Simeon1, Stefania Trino1, Ilaria Laurenzana1, Antonella Caivano1, Francesco La Rocca1, Oreste Villani2, Giovanna Mansueto2, Silvia Deaglio3, Idanna Innocenti4, Luca Laurenti4, Stefano Molica5, Giuseppe Pietrantuono2, Angelo De Stradis6, Luigi Del Vecchio7,8, Pellegrino Musto9.
Abstract
Microvescicles (MV) are shedding particles released by normal and neoplastic cells, whose levels in biological fluids highlight their potential role as disease biomarkers and therapeutic targets. By analyzing 131 newly diagnosed chronic lymphocytic leukemia (CLL), we found that the absolute number of serum CLL MV was significantly higher than in controls, in particular in advanced stages of disease. In addition, CD19 + and CD37+, B-cell derived MV, significantly correlated with high tumor burden. Absolute MV number cutoff selected by ROC analysis distinguished Rai stage 0 patients with shorter time to treatment (TTT) from those with more stable disease. Likewise, in the entire cohort, two groups of patients with different overall survival (OS) and different TTT were identified. At multivariate analysis, serum MV independently predicted for OS (along with Rai stage) and TTT (along with Rai stage, lymphocytes and CD38). In conclusion, circulating MV represent a new potential prognostic biomarker in CLL.Entities:
Keywords: Chronic lymphocytic leukemia; flow cytometry; microvesicles; prognosis
Mesh：
Substances：
Year: 2016 PMID： 27739922 DOI： 10.1080/10428194.2016.1243790
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022